Clinical trials in Gent – page 37

899 clinical trials in Gent, Belgium across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Gent at a glance

899

clinical trials

Research sites6

Quick filters

899 trials in Gent

Open in trial search

Respiratory syncytial virus infection

Not recruiting

Study on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease

Registered drugNo placebo

Study on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Escherichia infection

Not recruiting

Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

Registered drug

Study on the Safety and Immune Response of JNJ-78901563 and High-dose Influenza Vaccine in Preventing E. coli Infections in Adults Aged 65 and Older

Registered drug

Belgium

Participants:65+ years · Healthy volunteers
Substances:Ecoo15
Sponsor:Janssen Vaccines & Prevention B.V.

Contact Research Centre

Chronic rhinosinusitis with nasal polyps

Not recruiting

Study on Long-Term Safety and Efficacy of Lunsekimig for Adults with Chronic Rhinosinusitis with Nasal Polyps

InvestigationalNo placebo

Study on Long-Term Safety and Efficacy of Lunsekimig for Adults with Chronic Rhinosinusitis with Nasal Polyps

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:LUNSEKIMIG
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Respiratory syncytial virus infection+3

Not recruiting

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
Sponsor:GlaxoSmithKline Biologicals

Contact Research Centre

Influenza

Not recruiting

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo

Study on the Effectiveness of an MF59-Adjuvanted Influenza Vaccine Compared to a Non-Adjuvanted Vaccine in Adults Aged 65 and Older

Registered drugNo placebo

Belgium

Participants:65+ years · Healthy volunteers
Substances:A/DARWIN/9/2021 (H3N2) - LIKE STRAIN (A/DARWIN/6/2021, IVR-227)
Sponsor:Seqirus UK Limited

Contact Research Centre

Paranasal sinus inflammation+1

Not recruiting

Study on the Effectiveness and Safety of Brensocatib for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Registered drug

Study on the Effectiveness and Safety of Brensocatib for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Registered drug

Belgium

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:BRENSOCATIB
Sponsor:Insmed Inc.

Contact Research Centre

Obesity+1

Not recruiting

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational

Study on the Effectiveness and Safety of Maridebart Cafraglutide for Adults with Obesity or Overweight Without Type 2 Diabetes

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Maridebart Cafraglutide
Sponsor:Amgen Inc.

Contact Research Centre

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug

Study on the Effectiveness and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab for Patients with Moderate to Severe Plaque Psoriasis

Registered drug

Belgium

Participants:0–17 years · 18–64 years · 65+ years
Substances:Jnj-77242113
Sponsor:Janssen Cilag International

Contact Research Centre

Sjogren's syndrome

Not recruiting

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug

Study on the Effectiveness and Safety of Efgartigimod for Adults with Primary Sjögren's Syndrome

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of AMG 193 tablets for patients with advanced non-small cell lung cancer (NSCLC) who have previously received treatment and have MTAP gene deletion

InvestigationalNo placebo

Study of AMG 193 tablets for patients with advanced non-small cell lung cancer (NSCLC) who have previously received treatment and have MTAP gene deletion

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Amg 193
Sponsor:Amgen Inc.

Contact Research Centre

Asthma

Not recruiting

Study on the Effects of Lunsekimig (SAR443765) in Adults with High-Risk Asthma Not Eligible for Biologic Treatment

Investigational

Study on the Effects of Lunsekimig (SAR443765) in Adults with High-Risk Asthma Not Eligible for Biologic Treatment

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:LUNSEKIMIG
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Chronic rhinosinusitis without nasal polyps

Not recruiting

Study on the Effects of Itepekimab for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Investigational

Study on the Effects of Itepekimab for Patients with Chronic Rhinosinusitis Without Nasal Polyps

Investigational

Belgium

Participants:18–64 years · 65+ years
Substances:Itepekimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Gent

What the registry says about research in the country

01 Immunology and Vaccines

Multiple clinical trials focusing on vaccine development for various infectious diseases including influenza, RSV, and cytomegalovirus. Studies evaluating immune responses in both healthy volunteers and specific populations.

Influenza vaccine studies for adults 65+
RSV vaccine development
Varicella vaccine for children

Research includes evaluation of vaccine safety, immunogenicity, and effectiveness across different age groups.

02 Respiratory Medicine

Innovative research targeting chronic respiratory conditions and nasal health, including studies on rhinitis medicamentosa and chronic rhinosinusitis.

Nasal decongestant dependency treatment
Chronic rhinosinusitis management
Respiratory virus prevention

Trials focus on both therapeutic interventions and long-term disease management strategies.

03 Autoimmune and Inflammatory Conditions

Studies examining new treatments for inflammatory diseases including psoriasis, psoriatic arthritis, and biliary conditions.

Primary biliary cholangitis treatment
Psoriasis therapies
Immune system disorders

Research aims to improve treatment outcomes and quality of life for patients with chronic conditions.

Back to Belgium All countries